EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease

Luis Puig iD, Tsen-Fang Tsai iD, Enrique R Soriano iD, Tina Bhutani iD, Megan Miller iD, Alexa P Kollmeier, Shu Li, Hewei Li, Sarah Ofori iD, Jeffrey Pawlikowski, Elizabeth Adamson, Melinda Gooderham iD und 3 weitere

The Journal of Dermatology · 2026-07 · 53 (7) · 1026-1031

DOI: 10.1111/1346-8138.70314 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 01.06.2026. Verfasst von Luis Puig und 14 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de la Santa Creu i Santa Pau, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Latent Tuberculosis, Antibodies, Monoclonal, Humanized, Psoriasis, Arthritis, Psoriatic. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson and Johnson.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Certain psoriatic disease treatments, including tumor necrosis factor‐α inhibitors (TNFi), increase tuberculosis (TB) risk. Testing for latent TB infection (LTBI) before initiating systemic therapy has been standard practice for psoriasis (PsO) patients; however, updated consensus states routine testing is not required before initiating interleukin (IL)‐17 or IL‐23 inhibitors. This analysis reports safety outcomes in LTBI+ patients with moderate‐to‐severe PsO or active psoriatic arthritis (PsA) who received guselkumab for up to 5 years. Data were pooled from 11 phase 2/3 studies (7 PsO, 4 PsA). Guselkumab 100 mg was generally administered at Week 0, Week 4, then every 8 weeks (PsO studies) or every 4 or 8 weeks (PsA studies). Placebo‐randomized patients crossed over to guselkumab at Week 16 and Week 24 in PsO and PsA studies, respectively. Patients with active TB or a history of active TB were excluded. LTBI+ patients could participate if LTBI treatment was initiated before/with the first dose of study drug or if LTBI treatment was completed within 5 years before the first dose of study drug. Among 5 255 randomized patients, 374 (7.1%) had LTBI and received preventive treatment, most commonly isoniazid (82.1%) and rifampicin (11.8%). No new‐onset TB or LTBI reactivation occurred in any guselkumab‐treated patient. Through Year 1, liver transaminase elevations were more common in LTBI+ vs. LTBI− patients; ≤ 2% of LTBI+ patients had CTCAE Grade 3 elevations vs. 0.5% of LTBI− patients (no LTBI+ patients had Grade 4 elevations). From Year 1–5 (after ~98% of LTBI+ patients completed preventive treatment), transaminase elevations were generally similar among LTBI+ and LTBI− patients. The absence of observed TB risk in guselkumab‐treated patients suggests IL‐23 inhibitors may be better treatment options than TNFi in high‐risk patients, including those in TB‐endemic regions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Latent TuberculosisAntibodies, Monoclonal, HumanizedPsoriasisArthritis, PsoriaticHumansFemaleAdultRandomized Controlled Trials as TopicMaleTreatment OutcomeMiddle AgedAntitubercular AgentsInterleukin-23Clinical Trials, Phase II as TopicClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

guselkumabinterleukin‐23 inhibitorspsoriasispsoriatic arthritistuberculosis

Substanzen

Antibodies, Monoclonal, HumanizedguselkumabAntitubercular AgentsInterleukin-23

Autor:innen und Institutionen

  • Hospital de la Santa Creu i Santa Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • National Taiwan University Hospital, Taipei, Taiwan.
  • Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Synergy Dermatology, San Francisco, California, USA.
  • Johnson & Johnson, Spring House, Pennsylvania, USA.
  • Johnson & Johnson, San Diego, California, USA.

ORCID-Profile: Luis Puig, Tsen-Fang Tsai, Enrique R Soriano, Tina Bhutani, Megan Miller, Sarah Ofori, Melinda Gooderham, Angela Londoño Garcia, Mark Lebwohl, Peter Nash

Förderung

  • Johnson and Johnson

Zitieren

APA

Puig, L., Tsai, T. F., Soriano, E. R., Bhutani, T., Miller, M., Kollmeier, A. P., Li, S., Li, H., Ofori, S., Pawlikowski, J., Adamson, E., Gooderham, M., Londoño Garcia, A., Lebwohl, M., & Nash, P. (2026). Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. The Journal of Dermatology, 53(7), 1026-1031. https://doi.org/10.1111/1346-8138.70314

Vancouver

Puig L, Tsai TF, Soriano ER, Bhutani T, Miller M, Kollmeier AP, et al. Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease. The Journal of Dermatology. 2026;53(7):1026-1031. doi:10.1111/1346-8138.70314

BibTeX
@article{Puig2026,
  author = {Puig, Luis and Tsai, Tsen-Fang and Soriano, Enrique R and Bhutani, Tina and Miller, Megan and Kollmeier, Alexa P and Li, Shu and Li, Hewei and Ofori, Sarah and Pawlikowski, Jeffrey and Adamson, Elizabeth and Gooderham, Melinda and Londoño Garcia, Angela and Lebwohl, Mark and Nash, Peter},
  title = {Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease},
  journal = {The Journal of Dermatology},
  year = {2026},
  volume = {53},
  number = {7},
  pages = {1026--1031},
  doi = {10.1111/1346-8138.70314}
}
Kostenlos starten →